// App-Quantinova.ai

: Heterozygous CTC1 Variants in Acquired Bone Marrow Failure

Researchers

Presenter

  • Wenyi Shen

Principal Investigators

  • Cassandra M. Hirsch

  • Bartlomiej P. Przychodzen

  • Reda Z. Mahfouz

  • Tomas Radivoyevitch

  • Louis Williams

  • Mohammad Fahad B. Asad

  • Jaroslaw P. Maciejewski

Medical Centers

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang, China

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Gastroenterology (GU)

Disease

  • Aplastic anemia

  • Cirrhosis

  • Anemia

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Serum amyloid A

  • Telomerase reverse transcriptase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved